MX374533B - POLIMORFO CRISTALINO DE ACETATO DE 15ß-HIDROXI-OSATERONA. - Google Patents
POLIMORFO CRISTALINO DE ACETATO DE 15ß-HIDROXI-OSATERONA.Info
- Publication number
- MX374533B MX374533B MX2018013786A MX2018013786A MX374533B MX 374533 B MX374533 B MX 374533B MX 2018013786 A MX2018013786 A MX 2018013786A MX 2018013786 A MX2018013786 A MX 2018013786A MX 374533 B MX374533 B MX 374533B
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline polymorph
- hydroxy
- osaterone acetate
- osaterone
- acetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona una forma polimórfica cristalina A de acetato de 15ß-hidroxi-osaterona que tiene una estabilidad mejorada (estabilidad de almacenamiento, estabilidad de pulverización y características de absorción). En un espectro de difracción de rayos X de polvo, picos de difracción característicos de la forma polimórfica cristalina A de acetato de 15ß-hidroxi-osaterona aparecen a ángulos de difracción 2? de 9.6° ± 0.2°, 17.1° ± 0.2° y 20.2° ± 0.2°. La forma polimórfica cristalina A tiene un punto de fusión de 280 a 283 °C y es un cristal de prisma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016095382 | 2016-05-11 | ||
| PCT/JP2017/017619 WO2017195804A1 (ja) | 2016-05-11 | 2017-05-10 | １５β－ヒドロキシ－酢酸オサテロンの結晶多形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013786A MX2018013786A (es) | 2019-03-28 |
| MX374533B true MX374533B (es) | 2025-03-06 |
Family
ID=60267316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013786A MX374533B (es) | 2016-05-11 | 2017-05-10 | POLIMORFO CRISTALINO DE ACETATO DE 15ß-HIDROXI-OSATERONA. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10508130B2 (es) |
| EP (1) | EP3456729B1 (es) |
| JP (2) | JP7210278B2 (es) |
| KR (1) | KR102383617B1 (es) |
| CN (1) | CN109153701B (es) |
| AU (1) | AU2017264187B2 (es) |
| CA (1) | CA3021179C (es) |
| EA (1) | EA034965B1 (es) |
| ES (1) | ES2829578T3 (es) |
| MX (1) | MX374533B (es) |
| MY (1) | MY195203A (es) |
| PH (1) | PH12018502365A1 (es) |
| SG (1) | SG11201809127PA (es) |
| WO (1) | WO2017195804A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3456729B1 (en) * | 2016-05-11 | 2020-09-02 | ASKA Pharmaceutical Co., Ltd. | CRYSTALLINE POLYMORPH OF 15ß-HYDROXY-OSATERONE ACETATE |
| WO2021065027A1 (ja) * | 2019-10-02 | 2021-04-08 | あすか製薬株式会社 | 排尿障害改善剤 |
| EP4039328A4 (en) * | 2019-10-02 | 2023-10-25 | ASKA Pharmaceutical Co., Ltd. | Dysuria-alleviating agent |
| US20220110238A1 (en) | 2020-10-09 | 2022-04-14 | Deere & Company | Machine control using a predictive map |
| TW202241452A (zh) * | 2020-12-18 | 2022-11-01 | 日商Ａｓｋａ製藥股份有限公司 | 固形製劑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61204198A (ja) * | 1985-03-07 | 1986-09-10 | Teikoku Hormone Mfg Co Ltd | ２−オキサプレグナン化合物 |
| DE3663668D1 (de) | 1985-03-07 | 1989-07-06 | Teikoku Hormone Mfg Co Ltd | 2-oxa- or aza-pregnane compounds |
| JPS61204199A (ja) * | 1985-03-07 | 1986-09-10 | Teikoku Hormone Mfg Co Ltd | ２−アザプレグナン化合物 |
| JPS62195398A (ja) * | 1986-02-21 | 1987-08-28 | Teikoku Hormone Mfg Co Ltd | 黄体ホルモン剤 |
| JP2591640B2 (ja) * | 1988-02-04 | 1997-03-19 | 帝国臓器製薬株式会社 | 新規な２−オキサプレグナン化合物 |
| JP2980992B2 (ja) * | 1990-12-28 | 1999-11-22 | 帝国臓器製薬株式会社 | ６−ハロゲノ−２−オキサプレグナ−４，６−ジエン−３−オン化合物の製造方法 |
| JP2591640Y2 (ja) | 1993-05-13 | 1999-03-10 | 株式会社吉野工業所 | 液体収納袋 |
| EP3456729B1 (en) * | 2016-05-11 | 2020-09-02 | ASKA Pharmaceutical Co., Ltd. | CRYSTALLINE POLYMORPH OF 15ß-HYDROXY-OSATERONE ACETATE |
-
2017
- 2017-05-10 EP EP17796164.6A patent/EP3456729B1/en active Active
- 2017-05-10 CN CN201780028401.XA patent/CN109153701B/zh active Active
- 2017-05-10 CA CA3021179A patent/CA3021179C/en active Active
- 2017-05-10 KR KR1020187035313A patent/KR102383617B1/ko active Active
- 2017-05-10 WO PCT/JP2017/017619 patent/WO2017195804A1/ja not_active Ceased
- 2017-05-10 ES ES17796164T patent/ES2829578T3/es active Active
- 2017-05-10 JP JP2018517047A patent/JP7210278B2/ja active Active
- 2017-05-10 EA EA201892566A patent/EA034965B1/ru not_active IP Right Cessation
- 2017-05-10 SG SG11201809127PA patent/SG11201809127PA/en unknown
- 2017-05-10 AU AU2017264187A patent/AU2017264187B2/en active Active
- 2017-05-10 MY MYPI2018001883A patent/MY195203A/en unknown
- 2017-05-10 MX MX2018013786A patent/MX374533B/es active IP Right Grant
- 2017-05-10 US US16/095,782 patent/US10508130B2/en active Active
-
2018
- 2018-11-09 PH PH12018502365A patent/PH12018502365A1/en unknown
-
2021
- 2021-06-04 JP JP2021094176A patent/JP7241807B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021121645A (ja) | 2021-08-26 |
| ES2829578T3 (es) | 2021-06-01 |
| EP3456729A1 (en) | 2019-03-20 |
| US10508130B2 (en) | 2019-12-17 |
| EP3456729A4 (en) | 2019-05-22 |
| CA3021179C (en) | 2024-07-02 |
| AU2017264187A1 (en) | 2018-11-15 |
| EP3456729B1 (en) | 2020-09-02 |
| EA201892566A1 (ru) | 2019-04-30 |
| SG11201809127PA (en) | 2018-11-29 |
| EA034965B1 (ru) | 2020-04-13 |
| BR112018071950A2 (pt) | 2019-02-05 |
| KR102383617B1 (ko) | 2022-04-05 |
| JP7241807B2 (ja) | 2023-03-17 |
| PH12018502365A1 (en) | 2019-09-09 |
| MX2018013786A (es) | 2019-03-28 |
| JPWO2017195804A1 (ja) | 2019-03-07 |
| CN109153701A (zh) | 2019-01-04 |
| MY195203A (en) | 2023-01-11 |
| US20190127417A1 (en) | 2019-05-02 |
| CA3021179A1 (en) | 2017-11-16 |
| AU2017264187B2 (en) | 2021-02-18 |
| JP7210278B2 (ja) | 2023-01-23 |
| CN109153701B (zh) | 2021-02-02 |
| WO2017195804A1 (ja) | 2017-11-16 |
| KR20190004787A (ko) | 2019-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502365A1 (en) | Crystalline polymorph of 15b-hydroxy-osaterone acetate | |
| MY186531A (en) | Crystals | |
| HRP20211670T1 (hr) | Derivat difenilmetana u kristalnom obliku | |
| NZ757222A (en) | Crystalline forms of diazabicyclooctane derivative and production process thereof | |
| PH12015502809A1 (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
| WO2014136282A8 (en) | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | |
| WO2015017378A3 (en) | Novel copper-cysteamine and methods of use | |
| MY196077A (en) | Crystal Of 3,5-Disubstituted Benzene Alkynyl Compound | |
| JP2012099494A5 (es) | ||
| MX2018007887A (es) | Formas cristalinas de modulador selectivo del receptor s1p1 y método de preparación del mismo. | |
| MX2015013020A (es) | Polimorfos de sovaprevir y metodos de fabricacion de los mismos. | |
| PH12019502588B1 (en) | Crystal form c of sanzuohuangcaotong, preparation method and use thereof | |
| HK1220443A1 (zh) | 用作止痛药的全氢喹喔啉衍生物 | |
| WO2012052478A3 (en) | Topical gel composition | |
| EP4400167A3 (en) | Oxazole compound crystal | |
| AR082435A1 (es) | Valsartan altamente cristalino | |
| MX2023004668A (es) | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. | |
| JP2015115140A5 (es) | ||
| CO6700139A1 (es) | Forma cristalina delta de la sal de arginina de perdinoprilo, su procedimiento de preparación y las composiciones famacéuticas que la contienen | |
| MX2023010972A (es) | Formas polimorficas de compuestos y metodo de preparacion de los mismos y aplicacion de los mismos. | |
| CA3280578A1 (en) | Crystalline dipeptides useful in the synthesis of elamipretide | |
| MX2018013764A (es) | Cristal de derivado de quinolina. | |
| WO2013121439A3 (en) | Garenoxacin mesylate, process for preparation thereof, and crystalline form thereof. | |
| AR107441A1 (es) | Forma cristalina de cobicistat | |
| WO2017042837A3 (en) | Stable crystalline form of regadenoson |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |